HTR1A and depressive symptom measurement: The presented study is focused on the serotonin receptor 5-HT1A, which is a therapeutic target in many CNS diseases (depression, schizophrenia, anxiety, and cognitive disorders), and which might be utilized in the treatment of serotonin-dependent neoplastic diseases in the future [1,3,6].